Background - A new modified-release (MR) granule formulation of valproate (VPA) has been recently developed for the treatment of children with epilepsy. It consists of tasteless microspheres that can be sprinkled on soft foods and easily swallowed. There are no data on the effectiveness of this formulation in pediatric age. Aim of the study - To evaluate the effects of the abrupt switch from solution to VPA MR granules in children undergoing chronic treatment. Methods - We enrolled children receiving VPA solution as sole or adjunctive therapy and switched them to MR granules at identical dosages. VPA blood level, treatment efficacy (clinical and EEG data), tolerability (adverse reactions), palatability, ease of administration, and compliance were evaluated before switching (T0) and after 4weeks (T1). Results - Out of 112 enrolled children, 108 (96.4%) completed the evaluation. We observed no significant differences between the patients at T0 and T1 in VPA blood levels, treatment efficacy, tolerability, and compliance. MR granules were judged more palatable (P<0.05) and easier to administer (P<0.05) than solution by children and parents. At 6-month follow-up, all patients continued to use MR granules. Conclusion - Modified-release granule formulation of VPA may be a reliable alternative to solution for its convenience of use.

Effects of the abrupt switch from solution to modified-release granule formulation of valproate

VERROTTI DI PIANELLA, Alberto;AGOSTINELLI, SERGIO;CHIARELLI, Francesco;
2012

Abstract

Background - A new modified-release (MR) granule formulation of valproate (VPA) has been recently developed for the treatment of children with epilepsy. It consists of tasteless microspheres that can be sprinkled on soft foods and easily swallowed. There are no data on the effectiveness of this formulation in pediatric age. Aim of the study - To evaluate the effects of the abrupt switch from solution to VPA MR granules in children undergoing chronic treatment. Methods - We enrolled children receiving VPA solution as sole or adjunctive therapy and switched them to MR granules at identical dosages. VPA blood level, treatment efficacy (clinical and EEG data), tolerability (adverse reactions), palatability, ease of administration, and compliance were evaluated before switching (T0) and after 4weeks (T1). Results - Out of 112 enrolled children, 108 (96.4%) completed the evaluation. We observed no significant differences between the patients at T0 and T1 in VPA blood levels, treatment efficacy, tolerability, and compliance. MR granules were judged more palatable (P<0.05) and easier to administer (P<0.05) than solution by children and parents. At 6-month follow-up, all patients continued to use MR granules. Conclusion - Modified-release granule formulation of VPA may be a reliable alternative to solution for its convenience of use.
File in questo prodotto:
File Dimensione Formato  
Effects of the abrupt switch from solution to modified-release granule formulation of valproate..pdf

Solo gestori archivio

Descrizione: Clinical Commentary
Tipologia: PDF editoriale
Dimensione 119.39 kB
Formato Adobe PDF
119.39 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11564/269692
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact